Novel drugs based on the incretin system, such as, glucagon-like peptide-1 receptor agonists (GLP-1 RA) and dipeptidyl peptidase-4 inhibitors (DPP-4i), have been approved for the therapy of type 2 diabetes [5]. Here, GLP1R is linked to type 2 diabetes mellitus.